AR023819A1 - FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION - Google Patents

FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION

Info

Publication number
AR023819A1
AR023819A1 ARP000102084A ARP000102084A AR023819A1 AR 023819 A1 AR023819 A1 AR 023819A1 AR P000102084 A ARP000102084 A AR P000102084A AR P000102084 A ARP000102084 A AR P000102084A AR 023819 A1 AR023819 A1 AR 023819A1
Authority
AR
Argentina
Prior art keywords
kit
formulation
parts
peptidase
carboxy
Prior art date
Application number
ARP000102084A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9901572A external-priority patent/SE9901572D0/xx
Priority claimed from SE9901573A external-priority patent/SE9901573D0/xx
Priority claimed from SE9902902A external-priority patent/SE9902902D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR023819A1 publication Critical patent/AR023819A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Formulaciones farmacéuticas de un inhibidor de la carboxi-peptidasa U (CPU, carboxy-peptidase U) y a un inhibidor de la trombina en forma de una mezclaconjunta con un adyuvante, diluyente y/o vehículo, farmacéuticamente aceptables, y también se refiere a un equipo transportable (kit) de partes, a un métodopara el tratamiento y uso de las formulaciones para el tratamiento de una condicion en la cual se requiere o desea la inhibicion de la CPU y/o la inhibicion dela trombina.
ARP000102084A 1999-05-03 2000-04-28 FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION AR023819A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9901572A SE9901572D0 (sv) 1999-05-03 1999-05-03 New compounds
SE9901573A SE9901573D0 (sv) 1999-05-03 1999-05-03 New compounds
SE9902902A SE9902902D0 (sv) 1999-08-13 1999-08-13 New formulation

Publications (1)

Publication Number Publication Date
AR023819A1 true AR023819A1 (es) 2002-09-04

Family

ID=27355973

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102084A AR023819A1 (es) 1999-05-03 2000-04-28 FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION

Country Status (26)

Country Link
US (1) US6974800B1 (es)
EP (1) EP1181048B1 (es)
JP (1) JP2002543148A (es)
KR (1) KR100725206B1 (es)
CN (1) CN100518820C (es)
AR (1) AR023819A1 (es)
AT (1) ATE447964T1 (es)
AU (1) AU763772B2 (es)
BR (1) BR0010255A (es)
CA (1) CA2371217A1 (es)
CZ (1) CZ20013932A3 (es)
DE (1) DE60043297D1 (es)
EE (1) EE200100578A (es)
ES (1) ES2335383T3 (es)
HK (1) HK1042442B (es)
HU (1) HUP0201615A3 (es)
IL (1) IL145951A0 (es)
IS (1) IS6140A (es)
MX (1) MXPA01011044A (es)
MY (1) MY126962A (es)
NO (1) NO20015308L (es)
NZ (1) NZ515063A (es)
SK (1) SK15652001A3 (es)
TR (1) TR200103151T2 (es)
TW (1) TWI232106B (es)
WO (1) WO2000066152A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
CA2381801C (en) 1999-09-14 2009-12-08 Meiji Seika Kaisha, Ltd. Phosphonic acid derivative having inhibitory activity against carboxypeptidase b
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
JP2005516972A (ja) 2002-01-22 2005-06-09 ファイザー・インク 血栓疾患の治療のためのｔａｆｉ−ａ阻害剤として使用される３−（イミダゾリル）−２−アミノプロピオン酸
MXPA04009125A (es) * 2002-03-21 2004-12-07 Schering Ag Inhibidores de carboxipeptidasa b plasmatica.
US20100297099A1 (en) * 2005-06-24 2010-11-25 Lars Otto Uttenthal Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract
US9834527B2 (en) 2013-06-10 2017-12-05 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
FR1393338A (fr) 1964-01-08 1965-03-26 Rech S Pharma Et Scient Nouveau dérivé de la cystéine et sa préparation
US3766206A (en) 1971-11-03 1973-10-16 Pfizer 18beta-glycyrrheting acid amides useful as antiulcer agents
FR2266502A1 (en) 1974-04-08 1975-10-31 Synpharm Sa N-(2-thenoyl)-cysteine and esters - with mucolytic activity, prepd. from cysteine (esters) and thenoyl chloride
US4177277A (en) * 1977-01-17 1979-12-04 E. R. Squibb & Sons, Inc. Method for alleviating hypertension
US4113715A (en) 1977-01-17 1978-09-12 E. R. Squibb & Sons, Inc. Amino acid derivatives
JPS545949A (en) 1977-06-16 1979-01-17 Hisamitsu Pharmaceut Co Inc Novel cyclohexanecarboxylic acid and its derivatives
FR2430945A2 (fr) 1978-07-12 1980-02-08 Chauvin Blache Lab Nouveaux derives de la cysteine, leur procede de fabrication et leur application en therapeutique
US4708965A (en) 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
DE3838467C2 (de) 1988-11-12 1998-12-10 Agfa Gevaert Ag Fotografisches Aufzeichnungsmaterial
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
IT1249650B (it) 1991-05-29 1995-03-09 Poli Ind Chimica Spa N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
KR0173034B1 (ko) 1995-04-28 1999-03-30 성재갑 선택적 트롬빈 억제제
GB9525620D0 (en) * 1995-12-15 1996-02-14 Glaxo Group Ltd Chemical compounds
US5859271A (en) * 1996-04-15 1999-01-12 Virginia Commonwealth University Cytoprotective compounds
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US5993815A (en) * 1996-11-08 1999-11-30 University Of Vermont Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies

Also Published As

Publication number Publication date
PL356119A1 (en) 2004-06-14
TWI232106B (en) 2005-05-11
ATE447964T1 (de) 2009-11-15
CN100518820C (zh) 2009-07-29
SK15652001A3 (sk) 2002-07-02
EP1181048B1 (en) 2009-11-11
MY126962A (en) 2006-11-30
HUP0201615A2 (en) 2002-09-28
EE200100578A (et) 2003-02-17
ES2335383T3 (es) 2010-03-26
JP2002543148A (ja) 2002-12-17
IL145951A0 (en) 2002-07-25
US6974800B1 (en) 2005-12-13
IS6140A (is) 2001-11-01
HUP0201615A3 (en) 2006-07-28
KR100725206B1 (ko) 2007-06-07
EP1181048A1 (en) 2002-02-27
DE60043297D1 (de) 2009-12-24
NZ515063A (en) 2003-08-29
NO20015308L (no) 2001-12-03
HK1042442B (zh) 2010-04-09
MXPA01011044A (es) 2002-06-04
CN1350463A (zh) 2002-05-22
NO20015308D0 (no) 2001-10-30
AU763772B2 (en) 2003-07-31
HK1042442A1 (en) 2002-08-16
KR20020003386A (ko) 2002-01-12
CA2371217A1 (en) 2000-11-02
AU4447200A (en) 2000-11-17
TR200103151T2 (tr) 2002-04-22
WO2000066152A1 (en) 2000-11-09
BR0010255A (pt) 2002-02-13
CZ20013932A3 (cs) 2002-04-17

Similar Documents

Publication Publication Date Title
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de ''kit'', el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
WO2001041807A3 (en) Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction
NO20053277D0 (no) Hurtigvirkende farmasoytisk sammensetning.
HUP0301660A2 (hu) Neutrális endropeptidáz inhibitor (NEPI) vegyületek alkalmazása férfi szexuális mżködési zavar kezelésére és az azokat tartalmazó gyógyszerkészítmények
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
ECSP055525A (es) Inhibidores de cinasas de tirosina
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
AR044923A1 (es) Imidazoquinolinas sustituidas con sulfonamida
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
AR023819A1 (es) FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
MY128061A (en) A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
MY136386A (en) New combination of a betablocker and a cholesterol-lowering agent
PE20040596A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
AR035553A1 (es) Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos.
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
PA8519501A1 (es) Farnesil transferasa inhibidora del enantiomero de quinolina 1,2-anillado
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
IT1291895B1 (it) Preparazione farmaceutica fluida a base di nimesulide per uso orale e rinofaringeo
HUP0301915A2 (hu) Sildenafil és egyéb PDE5 inhibitor hatású vegyületek alkalmazása korai magömlés kezelésére szolgáló gyógyszerkészítmény elżállítására
WO2002051445A3 (en) An oral and parenteral pharmaceutical formulation comprising a low molecular weight thrombin inhibitor prodrug

Legal Events

Date Code Title Description
FB Suspension of granting procedure